ADX-2191 for Retinitis Pigmentosa

Duke Eye Center, Durham, NC
ADX-2191Phase 2Waitlist AvailableResearch Sponsored by Aldeyra Therapeutics, Inc.

Study Summary

This trial will test a new treatment for retinitis pigmentosa, a degenerative eye disease. Eight subjects will receive injections of the new drug in their worst seeing eye. Ocular structure and function will be evaluated.

Eligible Conditions
  • Retinitis Pigmentosa

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events (AEs)
Secondary outcome measures
Assessment for change in central subfield foveal thickness and ellipsoid zone area/width
Central retinal sensitivity
Change in dark-adapted retinal sensitivity
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: ADX-2191 Three InjectionsExperimental Treatment1 Intervention
Group II: ADX-2191 Six InjectionsExperimental Treatment1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a site

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
29 Previous Clinical Trials
4,025 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrolment slots in this experiment?

"Affirmative. According to clinicaltrials.gov, this medical investigation is actively searching for participants. It was first announced on July 14th 2022 and was most recently updated on September 26th 2022, with 8 recruits needed from a single location."

Answered by AI

What potential side-effects should be expected from the consumption of ADX-2191?

"ADX-2191 has been evaluated to have a safety score of 2 since there are studies that attest to its harmlessness but lack evidence advocating for its effectiveness."

Answered by AI

What is the current participation rate of this clinical experiment?

"Correct. Clinicaltrials.gov affirms that recruitment is still underway for this clinical trial, which was initially posted on July 14th 2022 and most recently revised on September 26th 2022. 8 patients need to be enrolled at one medical site."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
18 - 65
What site did they apply to?
Duke Eye Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I want to improve my eyesight.

How responsive is this trial?

Typically responds via
Most responsive sites:
  1. Duke Eye Center: < 48 hours
Average response time
  • < 2 Days
~4 spots leftby Sep 2024